BioXell Acquires Novel Compound From Roche
12. Januar 2007 01:54 ET
|
BioXell SpA
MILAN, Italy, Jan. 12, 2007 (PRIME NEWSWIRE) -- BioXell S.p.A. (SWX:BXLN) today announced its decision to exercise the option rights it acquired from Roche for BXL746, a novel vitamin D3 analogue....
BioXell Completes Recruitment for Phase IIb Trial of Elocalcitol in Benign Prostatic Hyperplasia
15. Dezember 2006 01:42 ET
|
BioXell SpA
MILAN, Italy, Dec. 15, 2006 (PRIME NEWSWIRE) -- BioXell S.p.A. (SWX:BXLN) today announced that it has completed recruitment on schedule for its Phase IIb trial of lead compound Elocalcitol in Benign...
Reminder -- BioXell's R&D Day in Zurich - Friday, October 13
09. Oktober 2006 13:30 ET
|
BioXell SpA
ZURICH, Oct. 9, 2006 (PRIMEZONE) -- BioXell (Frankfurt:B4X) announced the following reminder:
"Following the invitation sent on September 27, we wish to remind you that BioXell's R&D Day will...
BioXell: Invitation to R&D Day
27. September 2006 02:11 ET
|
BioXell SpA
ADVISORY, Sept. 27, 2006 (PRIMEZONE) -- BioXell is pleased to invite you to its R&D day, whose purpose will be to provide an in-depth overview of the Company's clinical and pre-clinical R&D...
BioXell Plans Phase IIb European Trial for Elocalcitol in Overactive Bladder
28. Juli 2006 02:07 ET
|
BioXell SpA
MILAN, Italy, July 28, 2006 (PRIMEZONE) -- BioXell S.p.A. (SWX:BXLN) today announced its plans to proceed with a Phase IIb clinical trial of its lead compound Elocalcitol in Overactive Bladder (OAB)....
BioXell Enters License Agreement with Merck & Co., Inc. for TREM-1 Product Candidate and TREM Platform
23. Mai 2005 07:11 ET
|
BioXell SpA
MILAN, Italy, May 23, 2005 (PRIMEZONE) -- BioXell SpA, the Italian biopharmaceutical company, today announced that it has signed an exclusive, worldwide license agreement with Merck & Co., Inc....
BioXell and ProSkelia Announce R&D Collaboration
12. Januar 2004 04:22 ET
|
BioXell SpA
MILAN, Italy and PARIS, Jan. 12, 2004 (PRIMEZONE) -- BioXell SpA and ProSkelia SAS today announced the signing of a collaborative agreement to research and develop drug candidates based on Vitamin D3...
BioXell's Phase IIa trial in BPH is fully enrolled
28. November 2003 04:16 ET
|
BioXell SpA
MILAN, Italy, Nov. 28, 2003 (PRIMEZONE) -- Milan, Italy, November 28, 2003 - BioXell SpA, today announced that it has completed patient enrolment in the Phase IIa trial of its novel lead compound,...
BioXell Expands its Scientific Advisory Board
13. Oktober 2003 03:10 ET
|
BioXell SpA
MILAN, Italy, Oct. 13, 2003 (PRIMEZONE) -- BioXell SpA, today announced the appointment of Professor Karl Erik Andersson and Professor Roger Bouillon to the Company's Scientific Advisory Board (SAB)....
BioXell Appoints Director, Business Development & Commercial Strategy
15. September 2003 04:22 ET
|
BioXell SpA
MILAN, Sept. 15, 2003 (PRIMEZONE) -- BioXell SpA, today announced the appointment of Meenu Chhabra, BSc, MBA as Director of Business Development and Commercial Strategy with immediate effect.
Ms...